PET biomarker–positive patients (essentially patients with preclinical Alzheimer’s disease), had “a significantly increased size of the foveal avascular zone. It was robustly positive,” Gregory Van Stavern, MD, a neurologist at Washington University School of Medicine in St. Louis, Missouri, said here at the American Academy of Neurology (AAN) 2018 Annual Meeting. {read more here}